Programs

By state-of-art computational protein design and deep learning-based prediction of protein-protein interaction combined with experimental methods, we create monoclonal antibodies (mAbs) against next-generation immunotherapeutic targets. These mAbs can be recreated into next-generation bispecific T-cell engagers, CAR-T receptor or antibody-drug conjugates.
Under development

TD-600E-DQB
TD-600E-A0
TD-12D-A02
TD-12D-C08
TD-NMP1-A02
TD-NMP1-A03
TD-175H-A02
TD-858R-A11